Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive...
Alzamend Neuro To Present Non-Clinical Data Update On Pharmacokinetics Of AL001, A Lithium Salicylate/L-Proline Co-crystal, As A Potentially Beneficial Lithium Sparing Treatment For Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder And Post-Traumatic Stress Disorder At The Society Of Toxicology 2025 Annual Meeting And ToxExpo
Alzamend Neuro 將在毒理學會 2025 年年會和 ToxExpo 上介紹水楊酸鋰/L-脯氨酸共晶體 AL001 的非臨牀藥代動力學數據更新，該藥代動力學可能有益於 1 型雙相情感障礙、阿爾茨海默氏病、重度抑鬱症和創傷後應激障礙
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer's Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder
演講主題是 AL001 的藥代動力學，一種水楊酸鋰/L-脯氨酸共晶體，它是一種潛在有益的節鋰療法，可用於 1 型雙相情感障礙、阿爾茨海默氏病、重度抑鬱症和創傷後應激障礙
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced it will have a poster presentation at the Society of Toxicology ("SOT") Annual Meeting and ToxExpo, being held from March 16-20, 2025, in Orlando, Florida.
Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）（「Alzamend」）是一家處於臨牀階段的生物製藥公司，專注於開發治療阿爾茨海默氏病（「阿爾茨海默氏症」）、躁鬱症（「BD」）、重性抑鬱症（「MDD」）和創傷後應激障礙（「PTSD」）的新產品，今天宣佈將在以下地點發佈海報毒理學會（「SOT」）年會和毒理學博覽會，將於2025年3月16日至20日在佛羅里達州奧蘭多舉行。
